Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Alx Oncology Holdings 

Healthcare US ALXO

1.645USD
0.12(7.52%)

Last update at 2026-06-22T20:00:00Z

Day Range

1.541.66
LowHigh

52 Week Range

0.402.66
LowHigh

Fundamentals

  • Previous Close 1.53
  • Market Cap228.75M
  • Volume863918
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-100.14000M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.11M
  • Diluted EPS TTM-1.84

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -101.69500M -134.85000M -160.80500M -123.41800M -83.48400M
Minority interest - - - - -
Net income -101.69500M -134.85000M -160.80500M -123.48200M -83.46300M
Selling general administrative 23.85M 26.09M 28.48M 29.04M 23.39M
Selling and marketing expenses - - 0.84M - -
Gross profit - -0.87200M -0.83600M 0.00000M 0.00000M
Reconciled depreciation 0.71M 0.87M 0.84M 0.34M 0.05M
Ebit - -133.12100M -159.24000M -127.77800M -83.55500M
Ebitda -100.84600M -132.24900M -158.40400M -127.43600M -83.47100M
Depreciation and amortization - 0.87M 0.84M 0.34M 0.08M
Non operating income net other - - - -0.26000M 0.08M
Operating income -100.84600M -142.46700M -170.27800M -127.43600M -83.55500M
Other operating expenses 100.85M 142.47M 170.28M 127.44M 83.56M
Interest expense 1.60M 1.73M 1.56M -4.36000M 0.01M
Tax provision 0.00000M 0.00000M 0.00000M 0.06M -0.02100M
Interest income 3.96M 9.37M 10.65M 4.28M -
Net interest income 2.36M 7.64M 9.08M 4.28M -0.01300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - 0.06M -0.02100M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 100.85M 142.47M 170.28M 127.44M 83.56M
Cost of revenue - 0.87M 0.84M 0.00000M 0.00000M
Total other income expense net -0.84900M 7.62M 9.47M 4.02M 0.07M
Discontinued operations - - - - -
Net income from continuing ops -101.69500M -134.85000M -160.80500M -123.48200M -83.46300M
Net income applicable to common shares - - - -123.48200M -83.46300M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 59.05M 147.78M 242.55M 306.49M 380.18M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 5.64M 5.70M 4.92M 4.76M 3.35M
Total liab 33.06M 34.16M 52.84M 43.02M 17.13M
Total stockholder equity 25.98M 113.62M 189.71M -325.46700M -201.98500M
Deferred long term liab - - - - 9.55M
Other current liab 14.42M 11.66M 25.84M 19.21M 0.26M
Common stock 0.05M 0.05M 0.05M 0.04M 0.04M
Capital stock 0.05M 0.05M 0.05M 0.04M 0.04M
Retained earnings -722.81700M -621.12200M -486.27200M -325.46700M -201.98500M
Other liab - - - 0.05M 1.84M
Good will - - - - -
Other assets - - - 9.01M 12.27M
Cash 16.37M 17.57M 22.41M 282.91M 363.67M
Cash and equivalents - - - - -
Total current liabilities 24.55M 18.50M 36.00M 28.32M 15.29M
Current deferred revenue - - - - 10.53M
Net debt -11.15600M -0.58900M -5.20900M -272.47600M -362.92500M
Short term debt 5.22M 2.35M 1.57M 1.04M 0.74M
Short long term debt 5.22M 0.43M - - -
Short long term debt total 5.22M 16.98M 17.20M 10.43M 0.74M
Other stockholder equity 748.72M 734.41M 675.68M 0.80M -0.04100M
Property plant equipment - - - 3.89M 0.90M
Total current assets 50.73M 134.35M 188.66M 270.97M 367.02M
Long term investments 3.49M 3.52M 35.41M 16.70M -
Net tangible assets - - - 263.46M 363.05M
Short term investments 28.42M 110.19M 160.33M 217.38M -
Net receivables 0.30M 0.89M 1.00M - -
Long term debt 4.53M 9.47M 9.64M 9.39M -
Inventory - - - - -
Accounts payable 4.91M 4.50M 8.59M 8.07M 3.76M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.03M 0.28M 0.26M -0.84500M -
Additional paid in capital - - - - -
Common stock total equity - - - 0.04M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -325.46700M -201.98500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.62M 0.27M 7.58M 9.01M 9.69M
Deferred long term asset charges - - - - -
Non current assets total 8.32M 13.42M 53.89M 35.52M 13.16M
Capital lease obligations - - 7.56M 1.04M 0.74M
Long term debt total - - - 9.39M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 82.80M 86.26M 44.66M -233.98900M -4.92300M
Change to liabilities - - - 10.56M 3.29M
Total cashflows from investing activities 82.59M 86.26M 44.66M -235.41600M -4.92300M
Net borrowings -1.36400M -0.82700M -0.38800M 9.35M -0.28100M
Total cash from financing activities 0.36M 30.82M 59.29M 9.86M 2.47M
Change to operating activities - - - 5.34M -7.31700M
Net income -101.69500M -134.85000M -160.80500M -123.48200M -83.46300M
Change in cash -1.19400M -4.83900M -26.41600M -314.77900M -70.55200M
Begin period cash flow 17.63M 22.47M 48.89M 363.67M 434.22M
End period cash flow 16.44M 17.63M 22.47M 48.89M 363.67M
Total cash from operating activities -84.14200M -121.91200M -130.36400M -89.22300M -68.10100M
Issuance of capital stock 0.00000M 0.00000M 58.89M 0.00000M 0.00000M
Depreciation 0.71M 0.87M 0.84M 0.34M 0.05M
Other cashflows from investing activities - - - - -4.25700M
Dividends paid - - 59.68M - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.02M 0.35M 0.52M 0.34M 0.20M
Other cashflows from financing activities 0.36M 31.64M 0.79M 9.35M 2.55M
Change to netincome - - - 23.84M 19.34M
Capital expenditures 0.21M 0.45M 1.27M 1.43M 4.92M
Change receivables - - - - -
Cash flows other operating - - - 0.42M -9.24000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -314.77900M -70.55200M
Change in working capital 0.34M -12.43000M 8.30M 9.85M -4.02700M
Stock based compensation 12.58M 27.09M 26.27M 23.84M 13.91M
Other non cash items 3.93M -2.59700M -4.96500M 0.23M 5.42M
Free cash flow -84.35400M -122.35900M -131.63800M -90.65000M -73.02400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ALXO
Alx Oncology Holdings 		 0.12 7.52% 1.65 - - 5085.96 8.88 4287.72 -2.349
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Alx Oncology Holdings 

323 Allerton Avenue, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Dr. Corey S. Goodman Ph.D. Independent Exec. Chairman 1951
Dr. Jaume Pons Ph.D. Founder, Pres, CEO & Director 1967
Mr. Peter S. Garcia M.B.A. Chief Financial Officer 1962
Ms. Shelly Pinto VP of Fin. & Chief Accounting Officer 1977
Dr. Sophia Randolph M.D., Ph.D. Chief Medical Officer & Director 1968
Dr. Michael Chang Ph.D. VP of Operations NA
Dr. Chris Byrd J.D., Ph.D. Gen. Counsel NA
Ms. Jeanne Y. Jew Chief Bus. Officer 1964
Dr. Athanasios Tsiatis M.D. Sr. VP of Clinical Devel. NA
Dr. Lin Yeong-Liang M.D., M.S. Sr. VP of Drug Safety & Pharmacovigilance NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.